Drugs / hepcortespenlisimut-L
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT02256514 | Sep 2014 → Sep 2019 | cirrhosis of liver, hepatocellular carcinoma | Immunitor LLC | Unknown | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT02232490 | Jan 2015 → Nov 2019 | hepatocellular carcinoma | Immunitor LLC | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | hepcortespenlisimut-L | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02232490 ↗ |
| Modality | Vaccine | “hepcortespenlisimut-L (V5) therapeutic vaccine against HCC” NCT02232490 ↗ |
| Route | Oral | “Daily oral dose of hepcortespenlisimut-L” NCT02256514 ↗ |